Navigation Links
High-Performing Healthcare Organizations Have Seven Qualities in Common
Date:3/25/2008

Three Healthcare Leaders Reveal Characteristics at National Conference

DALLAS, March 25 /PRNewswire/ -- Top-performing organizations share many of the same characteristics, processes and practices. Along with two other healthcare executives, Paul Spiegelman, founder and CEO of The Beryl Companies and author of "Why Is Everyone Smiling? The Secret Behind Passion, Productivity and Profit," revealed the seven simple truths of high-performing facilities at the recent American College of Healthcare Executives Annual Congress in Chicago.

"Healthcare organizations are being challenged to operate on the same principles as other retail and service businesses," said Spiegelman. "Market dynamics like transparency, consumerism and staffing shortages demand that healthcare executives seek ways to set their organizations apart as an employer of choice and a provider of exceptional customer service in addition to excellent clinical care."

Spiegelman's co-presenters, Britt Berrett, CEO of Medical City Dallas, and Jason Wolf, director of organization development Eastern Group for Hospital Corporation of America (HCA), shared their findings from a multi-facility study that uncovered the characteristics in common of HCA's highest-performing facilities. "Organizational performance does not require extensive, complicated plans, but rather clear commitments to simple, concise and sensible actions that lead to profound organizational outcomes," said Wolf. The HCA study revealed that high-performing facilities had more satisfied employees and patients, offered better quality and generated higher earnings.

The seven simple truths revealed at the ACHE Congress presentation include:

1. Visionary leadership

2. Consistent and effective communication

3. Select for fit and ongoing development of staff

4. Agile and open culture

5. Put service first

6. Ongoing recognition and community outreach

7. Solid relationship
'/>"/>

SOURCE The Beryl Companies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Methodist Healthcare - Memphis Hospitals Announces the Extension of Tender Offers
2. MarketResearch.com Announces Distribution of Wireless Healthcare Research
3. Three Out of Four Pennsylvania Voters Support Increased State Funding for Home Healthcare Services
4. DNV Healthcare Advances in Bid to Accredit Hospitals
5. AUDIO from Medialink and UnitedHealthcare: Medicare Open Enrollment Ends March 31
6. RxElite Awarded Anesthetic Gases Multi-Source Contract by Premier Inc., a Purchasing Network for More than 1,500 U.S. Hospitals and 49,000 Other Healthcare Sites
7. MEDai Assists Healthcare Organizations Demonstrate the Value of Predictive Modeling
8. Arthur J. Gallagher & Co. Acquires Healthcare Risk Solutions, LLC
9. Mirixas Healthcare Success in Software-as-a-Service and IT/Business Integration Recognized in Gartner Publication
10. eMPR Digital Drug Reference Reaches 50,000 Downloads and the Publisher Launches a Raffle for Healthcare Providers
11. Aflac Reaches $40 Million Milestone in Donations to the Aflac Cancer Center and Blood Disorders Service of Childrens Healthcare of Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/13/2008)...unkist Take a Stand Campaign Returns For Its Fifth... to Kids Raising Money For Charity, SHERMAN OAKS,...,Stand(R) campaign is back for a fifth year and bi...oud supporters Rubbermaid(R) and Domino(R)/C&H(R),... the distribution of,20,000 free lemonade stands t...
(Date:5/13/2008)...HARBIN, China, May 13 /Xinhua-PRNewswire-FirstCall...Medical, or ,the Company,) (OTC Bulletin,Board:...company for,external use, over-the-counter drugs i...nounced that the Company will present at the upcom...nference on May 19, 2008 at,the Waldorf Astoria in...
(Date:5/13/2008)...dbearing had no such benefit if baby was bottle-fe... (HealthDay News) -- Women who breast feed for mor...thritis (RA) by half, according to a new Swedish s...children but not breast-feeding offered women no p...ntraceptives also failed to reduce the risk of RA....
(Date:5/13/2008)...WELLINGTON, Fla., May 13 /PRNewswire-FirstCall/ --...hat its subsidiary, Renaissance Health System,of F...ne of its HMO,partners in South Florida to include...nded relationship will allow Renaissance to extend...contract will initially cover,South Florida, which...
Breaking Medicine News(10 mins):Health News:Kids Squeeze 'Aid' Out of Lemons as Take a Stand(R) Program Launches Nationwide 2Health News:Kids Squeeze 'Aid' Out of Lemons as Take a Stand(R) Program Launches Nationwide 3Health News:China Sky One Medical, Inc. to Present at Brean Murray Carret & Co. All-Cap All-China Conference 2Health News:Breast-feeding Might Shield Women From Rheumatoid Arthritis 2Health News:The Quantum Group Executes First Medicaid Service Contract with HMO 2Health News:The Quantum Group Executes First Medicaid Service Contract with HMO 3
... judge of Pakistan has ordered woman lawyers not t...mes reported Saturday//. "You are professionals an... Justice Tariq Pervaiz Khan of the Peshawar High C... Anjum, ordering the ban on veils. "We (the judges...
...on, Aimed at blocking lawyers' access to a high-pr...ernment called the interrogation //techniques "nat...use extremely grave damage", the Washington Post r...risoners at secret CIA prisons must not be allowed...
...r's disease was first diagnosed on November 3, 190...searchers //are now focusing on neuroscience, immu...tand the manner in which AD develops and progresse...earch Center, Emory University, feel that this stu...
...city of an individual's immune system to control H...c versions of key immune-system molecules// called...on the fragments of viral protein those molecules ... infected cells. In a report in the November issue...
Other Medicine News:Health News:Genes determine the capacity to fight HIV in early stages 2Health News:Genes determine the capacity to fight HIV in early stages 3
(Date:5/12/2008)...re-FirstCall/ -- GeoVax Labs, Inc. (OTC,Bulletin B...velopment,company, announced today that it has ent...ement with Fusion Capital Fund II, LLC, a Chicago-...ll up to $10 million of its common stock to Fusion...after the Securities and,Exchange Commission has d...
(Date:5/12/2008)...ination of Scaffolding, Deliverability and ...rael, May 12 /- Medinol is proud to a...llion(TM) CoCr Coronary Stent,enabling physicians...ically,innovative flexible closed cell design sten...ng the unprecedented,balance of flexibility and co...
(Date:5/12/2008)...ewswire-USNewswire/ -- GlaxoSmithKline (GSK),in c...BIG), a leading,academic breast cancer research ne...reast Cancer Cooperative Group (SOLTI), today anno...ill examine the role of TYKERB(R) in the,treatment...patinib and/or,Trastuzumab Treatment Optimization)...
(Date:5/9/2008)...wire-USNewswire/ -- Osteoarthritis is a,painful an...almost 50,million people in the United States. It ...ints. The novel investigational pain medication,ta...ded significant relief,for patients with joint-dis... and with fewer gastrointestinal side effects than...
Breaking Medicine Technology:GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 3TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 4TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 5TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 6TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 7Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm 28iloperidone 29 1445 1Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm 28iloperidone 29 1445 2Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm 28iloperidone 29 1445 3Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 1Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 2Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 3Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 4Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 5Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 1Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 2Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 3Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 1Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 2Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 3Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 5Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 6Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 7Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 8Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 9Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 10Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 11Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 12Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 13Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 14Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 15Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 16Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 17
...007 /PRNewswire/ -- Berlex, Inc., a U.S.,affiliate...oday the,results of a retrospective study demonstr... (NAbs) that can develop in response to,Betaseron(...inical,response in patients with multiple sclerosi...0 patients across three continents. It,is the larg...
...SINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics In...S.,Phase 2 study of Proellex(TM), an oral drug bei...ds. This study suggests that,treatment with Proell...mprovement in symptoms associated with uterine,fib...ils and Results , This 12 week, double-blind study...
Other Medicine Technology:Large Study Shows that Presence of Neutralizing Antibodies Did Not,Predict Clinical Response to Betaseron Treatment 2Large Study Shows that Presence of Neutralizing Antibodies Did Not,Predict Clinical Response to Betaseron Treatment 3Large Study Shows that Presence of Neutralizing Antibodies Did Not,Predict Clinical Response to Betaseron Treatment 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5
...mphony II Platelet Concentrate System is a point-o...f Platelet Concentrate (also referred to as Platel...P) from a small sample of blood. The Symphony II P... which are found in the platelets. The platelet co...
Autologous growth factors (AGF) technology. Using the patient's own blood, the AGF gel delivers a cocktail of naturally occurring growth factors and proteins in high concentrations that may enhance t
...th the introduction of the Leica Dual Imaging Colo...s with the latest available information technology...displayed now in the Leica M520 / M500 N optical p...huge amount of benefits: highest brightness, contr...
The Leica 2D video system offers you two smart solutions for microsurgical video imaging. The Leica 2D pick-up system, an integrated camera module to fit on all Leica M-series and the Leica 2D C-moun
Medicine Products: